Page 37 - Read Online

Page 16 of 16 Merhi et al. J Cancer Metastasis Treat 2021;7:42 https://dx.doi.org/10.20517/2394-4722.2021.80

84. Mocanu MM, Ganea C, Georgescu L, et al. Epigallocatechin 3-O-gallate induces 67 kDa laminin receptor-mediated cell death
accompanied by downregulation of ErbB proteins and altered lipid raft clustering in mammary and epidermoid carcinoma cells. J Nat
Prod 2014;77:250-7. DOI PubMed
85. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006;94:941-
6. DOI PubMed PMC
86. Sela-Passwell N, Rosenblum G, Shoham T, Sagi I. Structural and functional bases for allosteric control of MMP activities: can it pave
the path for selective inhibition? Biochim Biophys Acta 2010;1803:29-38. DOI PubMed
87. Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and their inhibitors: potential for the development of new
therapeutics. Cells 2020;9:1313. DOI PubMed PMC
88. Bjorklund M, Heikkila P, Koivunen E. Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks
tumor cell migration and invasion. J Biol Chem 2004;279:29589-97. DOI PubMed
89. Mantuano E, Inoue G, Li X, et al. The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes
migration of schwann cells by binding to low-density lipoprotein receptor-related protein. J Neurosci 2008;28:11571-82. DOI
PubMed PMC
90. Dufour A, Zucker S, Sampson NS, Kuscu C, Cao J. Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory
peptides. J Biol Chem 2010;285:35944-56. DOI PubMed PMC
91. Ollauri-Ibáñez C, Astigarraga I. Use of antiangiogenic therapies in pediatric solid tumors. Cancers (Basel) 2021:13. DOI PubMed
PMC
92. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet
2016;388:518-29. DOI PubMed
93. Schempp CM, Kiss J, Kirkin V, et al. Hyperforin acts as an angiogenesis inhibitor. Planta Med 2005;71:999-1004. DOI PubMed
94. Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a ‘modern’ herbal antidepressant: pharmacokinetics of active
ingredients. Clin Pharmacokinet 2006;45:449-68. DOI PubMed
95. Ang CY, Hu L, Heinze TM, et al. Instability of St. John’s wort (Hypericum perforatum L.) and degradation of hyperforin in aqueous
solutions and functional beverage. J Agric Food Chem 2004;52:6156-64. DOI PubMed
96. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is
mediated by the pregnane X receptor. J Pharmacol Exp Ther 2004;308:495-501. DOI PubMed
97. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John’s wort extracts on CYP3A: a systematic review of
prospective clinical trials. Br J Clin Pharmacol 2006;62:512-26. DOI PubMed PMC
98. Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavailability of hyperforin from hypericum extracts in rats and human
volunteers. Pharmacopsychiatry 1998;31 Suppl 1:36-43. DOI PubMed
99. Schulz HU, Schurer M, Bassler D, Weiser D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the
flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet
in healthy male volunteers. Arzneimittelforschung 2005;55:561-8. DOI PubMed
100. Franklin M, Chi J, McGavin C, et al. Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy
volunteers. Biol Psychiatry 1999;46:581-4. DOI PubMed
101. Gartner M, Muller T, Simon JC, Giannis A, Sleeman JP. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer
agent. Chembiochem 2005;6:171-7. DOI PubMed
102. Martinez-Poveda B, Verotta L, Bombardelli E, Quesada AR, Medina MA. Tetrahydrohyperforin and octahydrohyperforin are two
new potent inhibitors of angiogenesis. PLoS One 2010;5:e9558. DOI PubMed PMC
103. Chauvet S, Barras A, Boukherroub R, Bouron A. Lipid nanocapsules containing the non-ionic surfactant Solutol HS15 inhibit the
transport of calcium through hyperforin-activated channels in neuronal cells. Neuropharmacology 2015;99:726-34. DOI PubMed
104. Nosratabadi R, Rastin M, Sankian M, Haghmorad D, Mahmoudi M. Hyperforin-loaded gold nanoparticle alleviates experimental
autoimmune encephalomyelitis by suppressing Th1 and Th17 cells and upregulating regulatory T cells. Nanomedicine 2016;12:1961-
71. DOI PubMed
105. Füller J, Kellner T, Gaid M, Beerhues L, Müller-Goymann CC. Stabilization of hyperforin dicyclohexylammonium salt with
dissolved albumin and albumin nanoparticles for studying hyperforin effects on 2D cultivation of keratinocytes in vitro. Eur J Pharm
Biopharm 2018;126:115-22. DOI PubMed
106. Traeger A, Voelker S, Shkodra-Pula B, et al. Improved bioactivity of the natural product 5-lipoxygenase inhibitor hyperforin by
encapsulation into polymeric nanoparticles. Mol Pharm 2020;17:810-6. DOI PubMed